NEXIMMUNE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.38 USD | -5.85% |
|
+6.29% | +52.25% |
| Apr. 17 | North American Morning Briefing : Stock Futures -2- | DJ |
| Apr. 16 | NexImmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2022 | - | Sales 2023 | - | Capitalization | 2.35M |
|---|---|---|---|---|---|
| Net income 2022 | -62M | Net income 2023 | -32M | EV / Sales 2022 | - |
| Net cash position 2022 | 33.62M | Net cash position 2023 | 3.13M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-0.09
x | P/E ratio 2023 |
-0.07
x | Employees | 6 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 78.05% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -5.85% | ||
| 1 week | +6.29% | ||
| Current month | +0.60% | ||
| 1 month | -21.40% | ||
| 3 months | -62.36% | ||
| 6 months | +20.71% | ||
| Current year | +52.25% |
1 week
3.10
3.80
1 month
3.014.10
Current year
2.3228.69
1 year
1.2528.69
3 years
1.25489.50
5 years
1.25700.00
10 years
1.25700.00
| Managers | Title | Age | Since |
|---|---|---|---|
Kristi Jones
CEO | Chief Executive Officer | 60 | 17-05-31 |
Mathias Oelke
FOU | Founder | 56 | 11-06-06 |
Tonya Catterton
CMP | Compliance Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sol Barer
CHM | Chairman | 76 | 19-12-15 |
Zheng Bin Yao
BRD | Director/Board Member | 58 | 16-12-31 |
Alan Roemer
BRD | Director/Board Member | 54 | 17-01-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 3.38 | -5.85% | 23,466 |
| 24-05-07 | 3.59 | +1.99% | 71,616 |
| 24-05-06 | 3.52 | +6.02% | 10,295 |
| 24-05-03 | 3.32 | +6.41% | 37,434 |
| 24-05-02 | 3.12 | -1.89% | 14,102 |
Delayed Quote Nasdaq, May 08, 2024 at 04:30 pm EDT
More quotes
NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the bodyâs own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML); NEXI-002 in multiple myeloma (MM), and NEXI-003, a solid tumor product candidate for Human papillomavirus (HPV) related cancers. The Company provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The Company is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +52.25% | 4.63M | |
| +2.93% | 108B | |
| +8.82% | 105B | |
| +0.90% | 23.46B | |
| -14.60% | 21.72B | |
| -7.05% | 18.64B | |
| -38.55% | 17.45B | |
| -8.83% | 17.19B | |
| +5.51% | 13.99B | |
| +37.49% | 12.53B |
- Stock Market
- Equities
- NEXI Stock